Abstract | OBJECTIVE: METHODS: RESULTS: All 3 patients with at least 1 year of followup receiving mycophenolate mofetil experienced complete normalization of pulmonary function tests (including diffusing capacity for carbon monoxide) and resolution of dyspnea. They were also able to reduce their prednisone doses. The only patient with pre- and posttreatment chest computed tomography imaging had total resolution of her interstitial opacities. The patient with only 5 months of posttreatment followup experienced an improvement in diffusing capacity for carbon monoxide from 44% to 77% predicted, but no change in dyspnea. CONCLUSION:
|
Authors | Pamela A Morganroth, Mary Elizabeth Kreider, Victoria P Werth |
Journal | Arthritis care & research
(Arthritis Care Res (Hoboken))
Vol. 62
Issue 10
Pg. 1496-501
(Oct 2010)
ISSN: 2151-4658 [Electronic] United States |
PMID | 20506189
(Publication Type: Case Reports, Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Dermatomyositis
(complications, diagnosis, drug therapy)
- Female
- Follow-Up Studies
- Humans
- Lung Diseases, Interstitial
(complications, diagnosis, drug therapy)
- Male
- Middle Aged
- Mycophenolic Acid
(analogs & derivatives, therapeutic use)
- Retrospective Studies
|